Salute e Benessere

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB's (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech's development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane's R&D operations based in Campus Solna, at the Karolinska...
Nasdaq GlobeNewswire
20/03/2025

Brainomix Completes £14M ($18M) Series C Round to Advance Its Transformative AI…

The company has demonstrated a unique ability to impact treatment rates, with results showing that Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, a life-changing stroke treatment reducing disability. The company has demonstrated a unique ability to impact treatment rates, with results showing that Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical...
PR Newswire
20/03/2025

Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia…

"As BMS expands its presence and ensures the provision of a wider treatment portfolio across our therapeutic areas, we are poised to address even more vital health challenges. The leadership team is focused on building impactful collaborations within the healthcare landscape as we strive to achieve sustainable, long-term health outcomes for patients across the region." "As BMS expands its presence and ensures the provision of a wider treatment portfolio across our therapeutic…
PR Newswire
20/03/2025

Pharming Group announces first patient dosed in Phase II clinical trial of…

Multi-center clinical trial includes sites located in the US, UK and EUSecond Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs)CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been dosed...
Nasdaq GlobeNewswire
20/03/2025

Press release: Sequana Medical to Sponsor Liver Connect, 5th Annual Conference…

Sequana Medical to Sponsor Liver Connect, 5 thAnnual Conference of Chronic Liver Disease Foundation Ghent, Belgium – 20 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that it is a silver sponsor of the Chronic Liver Diease Foundation's (“CLDF”) 5th annual Liver Connect conference taking place in San Antonio…
Nasdaq GlobeNewswire
20/03/2025

IBA reports solid Full Year 2024 results

Read the entire full year 2024 results press release here Louvain-la-Neuve, Belgium, 20 March 2025- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2024 financial year. Record-high revenue and return to profitability in 2024 driven by well-executed backlog conversion Net sales rose 7% to €498.2 million1 , with Other Accelerators increasing by 18%Gross margin improvement to...
Nasdaq GlobeNewswire
20/03/2025

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1 , successful private placement and 67% reduction in operating cash burnSubstantial clinical and regulatory progress in 2024; further data readouts, product approvals and label extensions anticipated in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support...
Nasdaq GlobeNewswire
20/03/2025

Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for…

Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell depleter program has the potential to reset the immune systemAcquisition underpins path for Sanofi becoming leading immunology companySanofi to pay $600 million up frontParis, March 20, 2025.Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to...
Nasdaq GlobeNewswire
20/03/2025

Pearl Partners with Medit to Enhance AI-Powered Dental Diagnostics in Intraoral…

Medit Link is a centralized platform for dental clinics and labs that streamlines digital workflows, from intraoral scanning to patient communication tools. With the integration of Pearl's AI-powered diagnostic solutions, dental clinicians will be able to identify oral conditions and potential pathologies with ease, as well as communicate more effectively with patients using intuitive visuals that inform treatment plans. By simplifying the detection of teeth misalignment, cracks, calculus, teeth…
PR Newswire
20/03/2025

Medit Partners with Imagoworks to Enhance Edentulous Prosthetic Workflow

With this partnership, Medit users can effortlessly transfer high-precision scan data from Medit SmartX to AOX through MeditLink. Once the scan is received, AOX offers two service options: digital design or a full-service package that includes both temporary and final prosthetic fabrication. This integration will simplify the workflow, allowing clinicians and dental technicians to efficiently plan and execute treatment for edentulous cases. With this partnership, Medit users can effortlessly...
PR Newswire
20/03/2025

Molecular Glues Market to Register Stunning Growth During the Forecast Period…

Key Takeaways from the Molecular Glues Market Report Key Takeaways from the Molecular Glues Market Report Discover which therapies are expected to grab the molecular glues market share @Molecular Glues Market Report Molecular Glues Market Dynamics A novel approach using native mass spectrometry has significantly advanced theunderstanding of stabilization mechanisms of covalent molecular gluesby enabling the simultaneous detection of multiple protein species, shedding...
PR Newswire
19/03/2025

CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue |…

Ablynx NV's CABLIVI (caplacizumab-yhdp) Overview Ablynx NV's CABLIVI (caplacizumab-yhdp) Overview CABLIVI is an antibody fragment that targets von Willebrand factor (vWF) and is used to treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy. It works by binding to the A1-domain of vWF, preventing its interaction with platelets, which helps reduce vWF-mediated platelet adhesion and consumption...
PR Newswire
19/03/2025

Inventiva announces the schedule of publication and presentation of its 2024…

Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year...
Nasdaq GlobeNewswire
19/03/2025

Our Blood Institute Joins Velico's Blood Center Education Program

Dr. John Armitage, president and CEO of Our Blood Institute, added, "Saving lives is the core of our mission at OBI. We understand that 'every second counts' when treating heavily bleeding patients. We are honored to help advance this groundbreaking technology, which has the potential to transform emergency medical response for EMS agencies, the military and others who save lives in the field before hospital care is accessible." Dr. John Armitage, president and CEO of Our Blood…
PR Newswire
19/03/2025

HAVAS UNVEILS "NEUROVERSE" TO UNLOCK UNTAPPED MARKET POTENTIAL THROUGH…

This initiative marks a major industry shift; with 53% of Gen Z identifying as neurodivergent,³ brands that fail to embrace this shift risk losing both the next generation of creative talent and the loyalty of a highly influential consumer base. This initiative marks a major industry shift; with 53% of Gen Z identifying as neurodivergent,³ brands that fail to embrace this shift risk losing both the next generation of creative talent and the loyalty of a highly influential consumer base...
PR Newswire
19/03/2025

Myant Launches Care360: AI-Powered Precision Cardiac Assessments Delivered…

Proudly Canadian and globally launched, Myant pioneers world-first innovations in advanced materials, manufacturing at its two Ontario sites. With medical-grade Health Canada licensing, Myant is redefining healthcare with Myant Care360, a direct-to-patient and physician cardiac assessment service. Initially offering 14-day or longer cardiac assessments, delivered nationwide to the patients home within 24-48hrs, Myant Care360 will soon expand to include full-suite virtual cardiometabolic…
PR Newswire
19/03/2025

Trading in GN Store Nord shares by board members, executives and associated…

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated NameCharlotte Johs Reason for the notification Position/statusMember of the Board of DirectorsInitial...
Nasdaq GlobeNewswire
19/03/2025

Oral Care Market to Reach $70 Billion by 2032 -- Exclusive Report by Meticulous…

Download FREE PDF Brochure Of Oral Care Market - https://www.meticulousresearch.com/download-sample-report/cp_id=5927 Download FREE PDF Brochure Of Oral Care Market -https://www.meticulousresearch.com/download-sample-report/cp_id=5927 The global oral care market is experiencing significant growth, driven by the rising prevalence of gum diseases and dental caries, increasing awareness of oral health and hygiene, and the growing demand for dental aesthetics. Consumers are becoming more...
PR Newswire
19/03/2025

Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation…

The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods. The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies 2-8and over 200 peer-reviewed publications. Over the past 15 years, this...
PR Newswire
19/03/2025

New Novartis Phase III data demonstrate meaningful efficacy and safety results…

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Treatment with investigational OAV101 IT led to statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in sham control armSafety findings were consistent in both treatment-naïve and treatment-experienced patientsThese new data indicate the potential for OAV101 IT to be a clinically meaningful treatment...
Nasdaq GlobeNewswire
19/03/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 19 MARCH 2025 at 14.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on...
Nasdaq GlobeNewswire
19/03/2025

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

A company presentation will take place during the conference's Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference's Innovation track spotlights the most promising emerging biotech and healthcare companies advancing detection, treatment, and cures across critical oncology areas.Theriva's management team will be available for one-on-one meetings during the conference, interested investors should contact Theriva's investor relations representative as below. About...
Nasdaq GlobeNewswire
19/03/2025

Northwestern Medicine and Vitestro Collaborate to Advance Autonomous Robotic…

As part of this collaboration, Northwestern Medicine will participate in a multicenter clinical trial validating the performance and safety of Vitestro's Aletta™—the world's first Autonomous Robotic Phlebotomy Device™ (ARPD™). The goal of the study is to generate key clinical evidence to support adoption of automated phlebotomy as a scalable solution for U.S. hospital and outpatient blood draw centers. As part of this collaboration, Northwestern Medicine will participate in a multicenter...
PR Newswire
19/03/2025

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dying by 37% and the chance of heart-related death by 55%. Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine ,...
Nasdaq GlobeNewswire
19/03/2025
Altri  Comunicati